期刊
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
卷 136, 期 2, 页码 120-127出版社
WILEY
DOI: 10.1002/ijgo.12047
关键词
Antifibrinolytic agent; Antifibrinolytic therapy; Bleeding prophylaxis; Obstetric and gynecologic surgery; Surgical bleeding; Tranexamic acid
Background: The value of tranexamic acid ( TA) treatment as bleeding prophylaxis in major uterine surgery is unclear. Objectives: To evaluate the antihemorrhagic effect of prophylactic TA treatment in major benign uterine surgery. Search strategy: PubMed, Embase, Cochrane Library, and Web of Science were searched from 1980 to 2015 without language restriction using search terms related to major uterine surgery combined with TA. Selection criteria: Randomized controlled trials comparing prophylactic TA with placebo or no intervention in women undergoing elective major benign uterine surgery. Data collection and analysis: Basic information and outcomes were collected and meta-analyses performed. Main results: Sixteen trials were included, with five trials considered to have an overall low risk of bias. In cesarean delivery, TA significantly reduced intraoperative bleeding ( mean -136 mL, 95% confidence interval [ CI] - 189 to -83), blood loss of more than 1000 mL (relative risk 0.38, 95% CI 0.18-0.81), and blood transfusion (relative risk 0.32, 95% CI 0.17-0.59). In abdominal myomectomy, TA also significantly reduced intraoperative bleeding (mean - 251 mL, 95% CI - 391 to - 110). Conclusions: Prophylactic TA treatment significantly reduced operative bleeding in women undergoing elective cesarean delivery or abdominal myomectomy. Additional randomized trials with low risk of bias are needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据